The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
Overview
Pulmonary Medicine
Authors
Affiliations
Introduction: The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have been empirical. The International Association for the Study of Lung Cancer developed a multinational database to propose evidence-based revisions for the eighth edition of the TNM classification of MPM.
Methods: Data from 29 centers were submitted either electronically or by transfer of existing institutional databases. The M component as it currently stands was validated by confirming sufficient discrimination (by Kaplan-Meier analysis) with respect to overall survival (OS) between the clinical M0 (cM0) and cM1 categories. Candidate stage groups were developed by using a recursive partitioning and amalgamation algorithm applied to all cM0 cases.
Results: Of 3519 submitted cases, 2414 were analyzable and 84 were cM1 cases. Median OS for cM1 cases was 9.7 months versus 13.4 months (p = 0.0013) for the locally advanced (T4 or N3) cM0 cases, supporting inclusion of only cM1 in the stage IV group. Exploratory analyses suggest a possible difference in OS for single- versus multiple-site cM1 cases. A recursive partitioning and amalgamation-generated survival tree on the OS outcomes restricted to cM0 cases with the newly proposed (eighth edition) T and N components indicates that optimal stage groupings for the eighth edition will be as follows: stage IA (T1N0), stage IB (T2-3N0), stage II (T1-2N1), stage IIIA (T3N1), stage IIIB (T1-3N2 or any T4), and stage IV (any M1).
Conclusions: This first evidence-based revision of the TNM classification for MPM leads to substantial changes in the T and N components and the stage groupings.
Barreto I, Franckenberg S, Frauenfelder T, Opitz I, Lauk O JTCVS Open. 2025; 23:318-325.
PMID: 40061543 PMC: 11883679. DOI: 10.1016/j.xjon.2024.10.012.
Prognostic Indicator for Pleural Mesothelioma.
Yotsukura M, Yoshida Y, Nakagawa K, Watanabe S Ann Thorac Surg Short Rep. 2025; 2(4):597-602.
PMID: 39790586 PMC: 11708647. DOI: 10.1016/j.atssr.2024.05.011.
Kanayama M, Takenaka M, Manabe T, Yoshimatsu K, Oyama R, Matsumiya H Interdiscip Cardiovasc Thorac Surg. 2024; 40(1.
PMID: 39731746 PMC: 11742126. DOI: 10.1093/icvts/ivae223.
Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?.
Roca E, Aujayeb A, Astoul P Curr Oncol. 2024; 31(9):4968-4983.
PMID: 39329996 PMC: 11430569. DOI: 10.3390/curroncol31090368.
Contemporary management of mesothelioma.
Neilly M, Pearson J, Thu A, MacRae C, Blyth K Breathe (Sheff). 2024; 20(2):230175.
PMID: 39015660 PMC: 11250169. DOI: 10.1183/20734735.0175-2023.